OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:43 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

NCT05223673 · Institut de Recherches Internationales Servier · PHASE3 · terminated · last registry update 2024-08-20 · Colorectal cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not started due to strategic reasons.”–Registry record, Institut de Recherches Internationales Servier

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against TYMP in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision